You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

I-131

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia Trial in Worldwide (Iopofosine I 131 single dose,

Recruiting
  • Waldenstrom Macroglobulinemia
  • +8 more
  • Iopofosine I 131 single dose
  • +2 more
  • Redlands, California
  • +42 more
Dec 30, 2022

Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer Trial in Boston (Selpercatinib, Sodium Iodine I-131, rhTSH)

Not yet recruiting
  • Thyroid Cancer
  • +5 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Dec 20, 2022

Thyroid Cancer Trial in Bialystok (metformin, Radioactive iodine (I-131))

Not yet recruiting
  • Thyroid Cancer
  • Bialystok, Poland
    Department of Endocrinology, Diabetology and Internal Medicine,
Jul 26, 2022

Multiple Myeloma Trial in Ann Arbor (Iodine I 131 Tositumomab)

Active, not recruiting
Has Results
  • Multiple Myeloma
  • Iodine I 131 Tositumomab
  • Ann Arbor, Michigan
    University of Michigan
Mar 16, 2022

Thyroid Cancer Trial run by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (drug, radiation,

Recruiting
  • Thyroid Cancer
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 28, 2023

Neuroendocrine Tumors Trial in São Paulo (MIBG-I131)

Withdrawn
  • Neuroendocrine Tumors
  • MIBG-I131
  • São Paulo, SP, Brazil
    AC Camargo Cancer Center
May 13, 2022

Locally Advanced Solid Tumors, Metastatic Solid Tumors Trial in Edmonton ([131]I-IAZA)

Withdrawn
  • Locally Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
Jul 7, 2022

Follicular Lymphoma Trial in Chicago (Bortezomib and Tositumomab I-131)

Terminated
Has Results
  • Follicular Lymphoma
  • Bortezomib and Tositumomab I-131
  • Chicago, Illinois
    Rush University Medical Center
Oct 6, 2021

High-Grade Glioma Trial in New York, Houston, Madison (CLR 131)

Not yet recruiting
  • High-Grade Glioma
  • CLR 131
  • New York, New York
  • +2 more
Nov 3, 2022

Neuroblastoma, Childhood Metastatic Pheochromocytoma Trial in Philadelphia (131 I-Metaiodobenzylguanidine (131 I-MIBG), 131

Available
  • Neuroblastoma
  • Childhood Metastatic Pheochromocytoma
  • 131 I-Metaiodobenzylguanidine (131 I-MIBG)
  • 131 I-MIBG
  • Philadelphia, Pennsylvania
    The Children's Hospital of Philadelphia
Jul 11, 2022

Thyroid Nodule, Toxic or With Hyperthyroidism, Autonomous Thyroid Function, Thyroid Nodule; Hyperthyroidism Trial in Arnhem,

Recruiting
  • Thyroid Nodule, Toxic or With Hyperthyroidism
  • +5 more
  • Radiofrequency ablation
  • Radioactive iodine
  • Arnhem, Gelderland, Netherlands
  • +1 more
Dec 2, 2021

Differentiated Thyroid Cancer Trial in Leiden (rhTSH-stimulated I-124 dosimetry, Intra-therapeutic I-131 dosimetry)

Recruiting
  • Differentiated Thyroid Cancer
  • rhTSH-stimulated I-124 dosimetry
  • Intra-therapeutic I-131 dosimetry
  • Leiden, Zuid-Holland, Netherlands
    Leiden University Medical Center
Apr 8, 2022

Renal Tracer Elimination in Thyroid Cancer Patients Treated With

Completed
  • Thyroid Carcinoma
    • Jena, Thüringen, Germany
      University Hospital Jena
    Dec 15, 2022

    Brain and CNS Tumors, Intraocular Melanoma, Lung Cancer Trial in New York (genetic, other, radiation)

    Active, not recruiting
    • Brain and Central Nervous System Tumors
    • +9 more
    • DNA analysis
    • +4 more
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Oct 28, 2021

    HER2-positive Breast Cancer Trial in Shanghai (68Ga/131I-SGMIB-5F7)

    Not yet recruiting
    • HER2-positive Breast Cancer
    • 68Ga/131I-SGMIB-5F7
    • Shanghai, China
      Huashan Hospital
    Aug 1, 2023

    Kidney Cancer Trial in New York (Iodine-131 radiolabeled chimeric mAb G250 (131I-cG250))

    Completed
    Has Results
    • Kidney Cancer
    • Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)
    • New York, New York
      Memorial Sloan-Kettering Cancer Center
    Oct 3, 2022

    Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult

    Terminated
    • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
    • +9 more
    • Allogeneic Bone Marrow Transplantation
    • +7 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Oct 4, 2021

    Neuroblastoma, Neuroectodermal Tumors, Tumors Trial in United States (131I-MIBG, 131-MIBG + Vorinostat)

    Recruiting
    • Neuroblastoma
    • +2 more
    • San Francisco, California
    • +15 more
    Jan 7, 2022

    Thyroid Cancer Trial in New York (131 I-iodine (131-I), 124 I-iodine (124-I))

    Active, not recruiting
    • Thyroid Cancer
    • 131 I-iodine (131-I), 124 I-iodine (124-I)
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Apr 1, 2022

    Disseminated Neuroblastoma, Ganglioneuroblastoma, Localized Resectable Neuroblastoma Trial in United States (drug, radiation,

    Active, not recruiting
    Has Results
    • Disseminated Neuroblastoma
    • +5 more
    • Birmingham, Alabama
    • +22 more
    Mar 3, 2022

    Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Tumor Trial in Canada, United States (I-131-1095,

    Active, not recruiting
    • Metastatic Prostate Cancer
    • +4 more
    • Duarte, California
    • +26 more
    Aug 3, 2022

    Relapsed Neuroblastoma, Metastatic Pheochromocytoma Trial in Dallas (131 I-Metaiodobenzylguanidine, Potassium Iodide, G-csf)

    No longer available
    • Relapsed Neuroblastoma
    • Metastatic Pheochromocytoma
    • 131 I-Metaiodobenzylguanidine
    • +2 more
    • Dallas, Texas
      The University of Texas Southwestern Medical Center
    Apr 13, 2022

    Thyroid Cancer Trial in Beijing (Anlotinib HCl, Sodium Iodide I 131, Penpulimab)

    Recruiting
    • Thyroid Cancer
    • Anlotinib hydrochloride
    • +2 more
    • Beijing, China
      Peking Union Medical College Hospital
    Jan 18, 2022

    Melanoma Trial in Clermont-Ferrand ([131I]ICF01012 (therapeutic dose level 1), [131I]ICF01012 (therapeutic dose level 2),

    Recruiting
    • Melanoma
    • [131I]ICF01012 (therapeutic dose level 1)
    • +3 more
    • Clermont-Ferrand, France
    • +1 more
    Jan 27, 2022

    Neoplastic Disease, Glioblastoma, Glioblastoma Multiforme Trial (131I-IPA)

    Not yet recruiting
    • Neoplastic Disease
    • +2 more
    • (no location specified)
    Jul 6, 2022